<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03565458</url>
  </required_header>
  <id_info>
    <org_study_id>LG-DPCL018</org_study_id>
    <nct_id>NCT03565458</nct_id>
  </id_info>
  <brief_title>Gemigliptin, Dapagliflozin, Empagliflozin DDI Study</brief_title>
  <official_title>An Open-label, Randomized, Multiple-dose, Crossover Study to Evaluate Drug-drug Interaction Following Oral Administration of Gemigliptin and Dapagliflozin or Empagliflozin in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Chem</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Chem</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      gemigliptin,SGLT-2i DDI study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      LG-DPCL018 (gemigliptin,SGLT-2i DDI study) is to evaluate the safety and immunogenicity of
      gemilgliptin &amp; dapagliflozin and gemigliptin &amp; empagliflozin.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">April 5, 2018</start_date>
  <completion_date type="Anticipated">December 22, 2018</completion_date>
  <primary_completion_date type="Anticipated">August 20, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of gemigliptin, dapagliflozin, empagliflozin</measure>
    <time_frame>day1, day6, day7 0, 0.5, 1,1.5,2,2.5,3,4,5,6,8,12,16,24 hours</time_frame>
    <description>AUCτ</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of gemigliptin, dapagliflozin, empagliflozin</measure>
    <time_frame>day1, day6, day7 0, 0.5, 1,1.5,2,2.5,3,4,5,6,8,12,16,24 hours</time_frame>
    <description>Css,max</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>tss,max of gemigliptin, dapagliflozin, empagliflozin</measure>
    <time_frame>day1, day6, day7 0, 0.5, 1,1.5,2,2.5,3,4,5,6,8,12,16,24 hours</time_frame>
    <description>tss,max</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>minimum blood plasma concentration of gemigliptin, dapagliflozin, empagliflozin</measure>
    <time_frame>day1, day6, day7 0, 0.5, 1,1.5,2,2.5,3,4,5,6,8,12,16,24 hours</time_frame>
    <description>Css,min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of gemigliptin metabolite</measure>
    <time_frame>day1,day6,day7 0, 0.5, 1,1.5,2,2.5,3,4,5,6,8,12,16,24 hours</time_frame>
    <description>AUCτ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax)of gemigliptin metabolite</measure>
    <time_frame>day1,day6,day7 0, 0.5, 1,1.5,2,2.5,3,4,5,6,8,12,16,24 hours</time_frame>
    <description>Css,max</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>minimum blood plasma concentration(Css,min) of gemigliptin metabolite</measure>
    <time_frame>day1,day6,day7 0, 0.5, 1,1.5,2,2.5,3,4,5,6,8,12,16,24 hours</time_frame>
    <description>Css,min</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>metabolic ratio of gemigliptin</measure>
    <time_frame>day1,day6,day7 0, 0.5, 1,1.5,2,2.5,3,4,5,6,8,12,16,24 hours</time_frame>
    <description>metabolic ratio</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>gemigliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>gemigliptin single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dapagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dapagliflozin single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>gemigliptin and dapagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>co-administration of gemigliptin and dapagliflozin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>empagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>empagliflozin single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>gemigliptin and empagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>co-administration of gemigliptin and empagliflozin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemigliptin</intervention_name>
    <description>zemiglo 50mg,LG Chem</description>
    <arm_group_label>gemigliptin</arm_group_label>
    <arm_group_label>gemigliptin and dapagliflozin</arm_group_label>
    <arm_group_label>gemigliptin and empagliflozin</arm_group_label>
    <other_name>zemiglo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>forxiga, dapagliflozin 10mg</description>
    <arm_group_label>dapagliflozin</arm_group_label>
    <arm_group_label>gemigliptin and dapagliflozin</arm_group_label>
    <other_name>forxiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin</intervention_name>
    <description>jardiance 25mg, empagliflozin</description>
    <arm_group_label>empagliflozin</arm_group_label>
    <arm_group_label>gemigliptin and empagliflozin</arm_group_label>
    <other_name>jardiance</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male adults at age between 19 to 55 at the time of the screening

          2. Those whose BMI measurement result at screening visit is between 18 and 27 kg/m2

          3. Subject who has voluntarily decided to participate in this clinical trial and
             consented after listening all procedures and objects of this clinical trial

          4. subjects who is consented in writing to be sure to comply with the requirements of the
             clinical trial

        Exclusion Criteria:

          1. Subject who has past or present history of a clinically significant disease such as
             hepatic, renal, immunological, respiratory, musculoskeletal, endocrine, neurological,
             hemato-oncological, or cardiovascular disorder

          2. Subject showing hypersensitivity reaction or having a history of hypersensitivity
             reaction that is clinically significant to gemigliptin or dapagliflozin or
             empagliflozin ingredients, drugs that contain same class of ingredients or other
             drugs(DPP-4i, SGLT-2i).

          3. Subject who had infection disease or serious injury within 21 days before the
             randomization

          4. Subject with genetic problems such as galactose intolerance, Lapp lactose
             dehydrogenase deficiency or glucose-galactose uptake disorder

          5. Subject who do not have a medically approved contraceptive during the period of the
             clinical trial, or who plan to provide sperm

          6. Subject who have received a clinical trial drug or a bioequivalence study drug within
             90 days of the random allocation

          7. Those who have received a drug that can significantly affect the absorption,
             distribution, metabolism or excretion of the clinical trial drug within 30 days of
             randomization

          8. Subject who had whole blood donation within 60 days or component blood donation within
             30 days before the randomization

          9. subject who drinks the average amount per week exceeding 140 g of alcohol

         10. Subject whose daily average smoking amount exceeds 20 pieces per day

         11. Average daily grapefruit juice intake exceeding 2 cups

         12. Subject who had a systolic blood pressure less than 100 mmHg, greater than 150 mmHg,
             diastolic blood pressure less than 70 mmHg, or greater than 100 mmHg at the time of
             screening test

         13. Subject with a glomerular filtration rate of less than 60 mL / min / 1.73m^2
             calculated from serum creatinine values at the time of screening

         14. Subject whose blood creatinine, AST, ALT or γ-GT levels exceeded the upper limit of
             the reference range by 1.5 times the screening test

         15. Subject who do not show a negative response in the hepatitis B test, hepatitis C test,
             HIV test and syphilis test

         16. Subject who are sensitive to the ingredients of Yellow No. 5 or have an allergy
             history

         17. Subject who have clinically significant abnormalities in other clinical tests

         18. Subject with clinically significant abnormal ECG findings

         19. Subject who is considered to be unsuitable in conducting the clinical trial at the
             principal investigator's discretionary judgment
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>jungryul kim, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>samsung seoul medical center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LG chem</name>
      <address>
        <city>Seoul</city>
        <state>Gangseo-Gu</state>
        <zip>07795</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>May 24, 2018</study_first_submitted>
  <study_first_submitted_qc>June 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2018</study_first_posted>
  <last_update_submitted>June 11, 2018</last_update_submitted>
  <last_update_submitted_qc>June 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol</mesh_term>
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

